What question did this study set out to answer?

To evaluate the impact of treatment delay and early biologic therapy on clinical outcomes in hidradenitis suppurativa.

June 18, 2026Dermatologic TherapyOpen Access

Therapeutic Delay and Biologic Response in Hidradenitis Suppurativa: A Real‐World Cohort Study

View Full Paper

Ask AI

Bookmark

To evaluate the impact of treatment delay and early biologic therapy on clinical outcomes in hidradenitis suppurativa.
Retrospective cohort study of 152 patients treated from December 2022 to March 2025.
Disease severity measured using the International Hidradenitis Suppurativa Severity Score System (IHS4) and Hurley stage.
Statistical analyses conducted including Mann–Whitney U tests and Cox regression.
Patients receiving biologic therapy had a mean IHS4 of 13.7 compared to 3.8 in nonbiologic therapy (p < 0.001).
Significant improvement observed in biologic-treated patients (ΔIHS4: −7.6 vs. −2.2; p < 0.001).
Therapeutic delay inversely predicted clinical response (Cox regression p = 0.045).

No takes yet. Share an insight, caveat, or question.

Real-world cohort study assesses treatment outcomes in hidradenitis suppurativa, highlighting implications of therapeutic delay.

Gencebay et al. (2026) studied this question.

View Full Paper

Ask AI

Bookmark